HopeStage
Back to all studies
CompletedNCT05321602

LY03010 dose and injection site research in schizophrenia

About this titleRead the official source — NCT05321602
Medication studyAges 18–65United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
Little Rock and 8 more locationsSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: September 8, 2021
Recruitment status
Completed
Enrollment listed in the registry
89
Sponsor
Luye Pharma Group Ltd.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT05321602
Official title
Show the full official title

A Randomized, Single-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Little Rock · Garden Grove · Orange

6 more locations
  • Torrance
  • Miami Lakes
  • Atlanta
  • Chicago
  • Gaithersburg
  • DeSoto

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Luye Pharma Group Ltd., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid and LY03010 351 mg treatment group, gluteal.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies